
SAPPHIRE Trial: Apitegromab Boosts Motor Function in SMA, Published in The Lancet Neurology
Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…












